Understanding the Influenza A H1N1 2009 Pandemic by Al-Muharrmi, Zakariya
SQU Med J, August 2010, Vol. 10, Iss. 2, pp. 187-195, Epub. 19th Jun 10
Submitted: 21st Oct 09
Revision Req. 11th Jan 10,  Revision Recd. 28th Feb 10
Accepted: 22nd Mar 10
In the last few years, the world has faced two major disasters. The first was economical recession; the second was the 
pandemic spread of a new reassortant influenza 
virus that spread all over the world in few weeks. 
Economic recession is clearly man-made, with 
economic mismanagement leading to the collapse 
of international banks, but pandemic viruses occur 
naturally and man has to struggle with nature for 
his survival. On 17th April 2009, the Center of 
Disease Control and Prevention (CDC), in the 
USA, reported a new Influenza A H1N1 strain 
with quadruple segment translocation in its RNA.1 
Since then this strain has spread worldwide and on 
11th June 2009 it was declared by the World Health 
Organization (WHO) to be a Phase 6 pandemic 
virus (maximum threat).2 Influenza pandemics 
have many effects on people, health care services 
and countries. The pandemic spread of influenza 
viruses is characterised by a high attack rate and 
Department of Microbiology & Immunology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman
Email: almuharrmi@gmail.com
 A  H1N1  2009 فهم وباء أنفلونزا
زكريا املحرمي
اإنتقال حلقي  A مع  اأنفلونزا  امللخ�ص:  يف اأبريل �شنة 2009 ظهرت يف الوليات املتحدة الأمريكية واملك�شيك �شاللة جديدة من فريو�شات 
ال�شاللة  لهذه  الوراثية  املادة   .)A H1N1 2009 ( رباعي يف احلم�س النووي الريبي اأدت اإىل تف�شي وباء، وقد �شنفت على اإنها اإنفلونزا
وباًء جائحا  ال�شاللة  هذه  العاملية  ال�شحة  منظمة  ناجتة عن ثالث �شاللت خمتلفة من الب�رش والطيور واخلنازير. ويف يونيو 2009 اأعلنت 
اأ�رشع  اجلديدة  ال�شاللة  وتنتقل  التنف�شية،  الُقَطريات  الأنفلونزا من خالل  ينتقل فريو�س  عاما.   40 منذ  ت�شجيله  يتم  وباء عاملي  اأول  ليكون 
من غريها من �شاللت الإنفلونزا مما يوؤدي اإىل �شعوبة ال�شيطرة على العدوى. غالبية احلالت امل�شابة بال�شاللة اجلديدة كانت خفيفة لكن 
بع�س املر�شى ح�شلت لديهم م�شاعفات والبع�س الآخر توفى. معظم الفحو�س املخربية لهذه ال�شاللة غري ح�شا�شة ما عدا تفاعل البوليمرييز 
دواء  مثل  النيورمينديز  لأنزمي  امل�شادة  لالأدوية  ت�شتجيب  اجلديدة  الوبائية  ال�شاللة  عالية.  خربات  ويتطلب  الثمن  باه�س  وهو  املت�شل�شل 
�شحنه للقاحات  اأول  توفري  مت   2009 الأو�شيلتامفري والزمنفري، لكن �شجلت بع�س احلالت املقاومة لالأو�شيلتامفري. ويف منت�شف �شبتمرب 
ال�شاللة اجلديدة وكانت فعاليتها املناعية عالية جدا دون ت�شجيل اأعرا�س جانبية تذكر.  اإن الرت�شد مهم جدا يف جميع مراحل الوباء اجلائح 
امل�شببة  الإنفلونزا  فهم فريو�شات  هو  املراجعة  هذه  الهدف من  امل�شتقبل،  الأوبئة يف  ومنع حدوث  الفريو�شية  العدوى  نزعة  ور�شد  لك�شف 
لالأوبئة اجلائحة ودرا�شة ال�شرتاتيجيات الالزمة ملراقبتها وتخفيف حدتها وال�شيطرة عليها.  
مفتاح الكلمات: الأنفلونزا، الوباء اجلائح، تفاعل البوليمرييز املت�شل�شل، اللقاح، الرت�شد.
abstract: A new strain of Influenza A virus, with quadruple segment translocation in its RNA, caused an 
outbreak of human infection in April 2009 in USA and Mexico. It was classified as Influenza A H1N1 2009. The 
genetic material originates from three different species: human, avian and swine. By June 2009, the World Health 
Organization (WHO) had classified this strain as a pandemic virus, making it the first pandemic in 40 years. 
Influenza A H1N1 2009 is transmitted by respiratory droplets; the transmissibility of this strain is higher than 
other influenza strains which made infection control difficult. The majority of cases of H1N1 2009 were mild and 
self limiting, but some people developed complications and others died. Most laboratory tests are insensitive 
except the polymerase chain reaction (PCR) which is expensive and labour intensive. The Influenza A H1N1 
2009 virus is sensitive to neuraminidase inhibitors (oseltamivir and zanamivir), but some isolates resistant to 
oseltamivir have been reported. A vaccine against the new pandemic strain was available by mid-September 2009 
with very good immunogenicity and safety profile. Surveillance is very important at all stages of any pandemic to 
detect and monitor the trend of viral infections and to prevent the occurrence of future pandemics. The aim of this 
review is to understand pandemic influenza viruses, and what strategies can be used for surveillance, mitigation 
and control.
Keywords: Influenza; Pandemic; Polymerase Chain Reaction; Vaccine; Surveillance.
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an increased level of mortality particularly in 
young adults. Therefore, it necessary to understand 
influenza viruses that cause pandemics and what 
strategies can be used for surveillance, mitigation 
and control.
The Virus
The influenza virus belongs to Orthomyxoviridae 
family. It has three classes: A and B which only infect 
humans and C which is uncommon. Its genetic 
material is made up of eight separate segments.3 
The virus is enveloped with two important 
projections on the surface, these are haemagglutinin 
that binds to cell receptors in target tissues and 
neuraminidase that cleaves to the sialic acid in the 
cell wall to release the progeny viruses. Influenza 
A has 16 different haemagglutinins and 9 different 
neuraminidases.4 It is classified according to the 
types of haemagglutinin and neuromindase on its 
surface, e.g. H1N1, H3N2 and H5N1. It infects not 
only humans, but also other mammals mainly pigs, 
birds and horses.3 Two types of genetic mutations 
occur in the influenza A virus. First, genetic drift 
which is a point mutation leading to a mild changes 
on surface antigens, leading to new variant of the 
same virus which causes the recurrent epidemic 
influenza infections. Second, genetic shift which 
occurs when genetic segments are translocated 
among Influenza A viruses from different species 
e.g. human, birds and pigs leading to a completely 
new strain not previously existing in nature.3 Such 
strains can cause pandemic infections if they have 
the ability to infect humans and the ability to be 
transmitted from one person to another. 
The current Influenza A H1N1 2009 strain is a 
result of genetic translocation from three different 
species: one genetic segment from human Influenza 
A H3N2, two segments from avian Influenza A 
H1N1 and five segments from swine H1N1.5 In 
1998, a new triple reassortant swine influenza virus 
was identified in North America. Genetically it was 
made up of five segments derived from the North 
American classical A/H1N1swine virus, while the 
polymerase gene segments derived from either 
birds or humans. Genetic analysis of the influenza A 
H1N1 2009 showed that it was derived from a new 
reassortment of six gene segments from the known 
triple reassortant swine virus.6 The genes encoding 
neuraminidase and the M protein were most closely 
related to those in influenza A viruses circulating in 
swine populations in Eurasia.5 Within a few months, 
the A H1N1 2009 virus became the predominant 
influenza strain worldwide.7 Compared to seasonal 
strains, A H1N1 2009 replicates more efficiently 
and produces different cytokines resulting in more 
lung damage in animal models.8
History and Phases of 
Pandemic Influenza
Influenza pandemics occur in waves. The WHO 
uses a six-phased approach to guide national 
preparedness plans against pandemics.9 Phases 1–3 
correlate with preparedness while phases 4–6 signal 
the need for mitigation efforts. In Phase 1, no viruses 
circulating among animals have been reported 
to cause human infection. In Phase 2, an animal 
influenza virus is known to have caused infection 
in humans. In Phase 3, an animal or human-
animal influenza reassortant virus has caused small 
clusters, but has not resulted in human-to-human 
transmission sufficient to sustain community-level 
outbreaks. Phase 4 occurs when such viruses cause 
human-to-human transmission at community-
level. In Phase 5, the human-to-human spread of 
the virus attacks at least two countries in one WHO 
region. If the outbreak is recorded in more than 
one WHO region, the final “pandemic phase”, or 
Phase 6, is declared.9 In the post-pandemic period, 
influenza disease activity returns to levels normally 
seen for seasonal influenza.9 The Influenza A H1N1 
virus was declared Phase 6 by the WHO on 11th 
June 2009.2
Global pandemics have been observed for 
several hundred years. The best documented 
pandemic occurred in 1918 (A (H1N1), Spanish 
flu).10 It was estimated to have infected 50% of the 
world's population, with an estimated mortality of 
40–50 million (mortality rate of 2–2.5%). The attack 
and mortality rates were highest among healthy 
adults (20–40 years old). The second was in 1957 
(A(H2N2), Asian flu) which affected around 40–50% 
of people during two waves, with a mortality rate of 
1 in 4000 and the total death toll probably exceeding 
1 million. The third was in 1968 (A(H3N2), Hong 
Kong flu) with similar morbidity and mortality to 
Asian Flu.11 Aspirin use which is known to cause 
hyperventilation and pulmonary oedema in high 
doses, was the major factor in the high death rate 
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to illness onset until the resolution of fever or until 
5 to 7 days after the onset of symptoms.5 The attack 
rate of A H1N1 2009 was estimated to be between 
20–30%.21
In a community setting the mitigation strategies 
for a pandemic depend on its level of severity and 
this is determined by the infectivity and case fatality 
rates. For low-severity pandemics with case fatality 
rates <0.5% and infectivity of 1.6 or below, such 
as the current pandemic, the preferred policy is a 
combination of social distancing with the use of 
antivirals for treatment and prophylaxis without 
school closure.22 School closure is a debatable 
option; the main reason for closure would be a high 
level of transmission leading to focal outbreaks and 
staff absenteeism.23 The greatest benefits of school 
closures are achieved when schools are closed very 
early on during an outbreak, ideally before 1% of 
the population falls ill;24 however, school closure 
have not shown benefits in previous outbreaks.23 
Regulations taken by national and international 
authorities to control the A H1N1 2009 pandemic 
need to address human rights according to Siracusa 
Principles. These principles states that social 
restriction should be: 1) in accordance with the 
law; 2) in the interest of a legitimate objective; 3) 
strictly necessary; 4) using the least intrusive or 
restrictive means available; 5) neither arbitrary nor 
discriminatory, and 6) subject to review.25 Each 
country should have a complete preparedness plan 
for pandemic control. However, this is lacking in 
most countries which respond to such disasters out 
of fear or from economic and political self-interest 
rather than with policies based on scientific fact; 
even the WHO and the CDC lack key powers and 
resources to control pandemic viruses efficiently.26
Clinical Presentation
The majority of cases of influenza A H1N1 2009 were 
mild and self limiting.8 The clinical presentation of 
influenza A H1N1 2009 is similar to those seen in 
seasonal influenza, with fever in 94% of patients, 
cough in 92% and sore throat in 66%.27 In admitted 
patients, the prevalence of symptoms is as follows: 
fever  (95%); cough  (88%); shortness of breath 
(60%); fatigue/weakness  (43%); rhinorrhoea  (38%); 
myalgias  (36%); headache  (34%); sore throat  (31%); 
vomiting  (29%); wheezing  (26%) and diarrhoea 
(24%).28 The time between onset of symptoms and 
from Spanish flu.12 Other possible factors could 
be the unavailability of antibiotics which were not 
yet discovered to treat bacterial superinfection; 
primitive infection control practices and the 
destruction of health care facilities as a result of 
World War I.
The first cases of the new pandemic influenza A 
H1N1 2009 infections were identified in April 2009 
in the United States.1 By August 2009, the cumulative 
number of infections in the United States alone was 
estimated to be at least 1 million.13 However, there 
were only 556 confirmed deaths,14 i.e. the mortality 
rate was only 0.056%. 
Infection Control and 
Mitigation Strategies
Influenza viruses are transmitted by respiratory 
droplets, which do not normally travel more than 
one metre distance although coughing and sneezing 
can increase this distance by a few more metres. 
The virus can survive for 6 hours on a dry surface; 
when touched by hands it can be retransmitted. 
Transmissibility of the A H1N1 2009 strain is higher 
than that of seasonal influenza strains.15 
Controlling the spread of influenza in a hospital 
setting is difficult and should include the following: 
isolating patients with suspected or documented 
influenza; sending home health care workers 
(HCW) with influenza-like illnesses and advising 
visitors showing symptoms of influenza not to 
come to hospital.16 Hand washing with water and 
soap or alcohol-based hand sanitiser should be 
universal policy although some reports claim soap 
and water to be more effective than alcohol.17 It is 
recommended to keep one metre distance between 
sick and healthy people and the patient should cover 
his/her mouth and nose when sneezing or coughing. 
If the patient is admitted in to hospital, a droplet 
isolation policy should be followed; this requires a 
side room with normal pressure ventilation. HCW 
should wear surgical face masks when caring 
for patients with influenza. Respirators, e.g. N95 
masks, are indicated for HCW doing invasive 
procedures in the respiratory tree, e.g. intubation 
or bronchoscopy.18 Some researchers claim surgical 
face masks to be as effective as N95 masks in the 
prevention of seasonal influenza.19 Others claim 
they are ineffective against A H1N1 2009.20 The 
patient is considered infectious from one day prior 
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admission to the hospital ranged from 4 to 25 days.29 
In Australia and New Zealand, the rate of ICU 
admission was 28.7 cases per million inhabitants.30 
The major determinants of ICU admission are: a) 
shortness of breath, which was seen in (87%) of 
admitted patients, and b) chest radiograph results 
consistent with pneumonia  (seen in 73%), compared 
with 51% and 28% in those not admitted to the ICU.28 
Major complications of influenza include viral 
pneumonia, peripheral neuropathy, encephalitis, 
myocarditis and myositis.31 These are mainly seen 
in people with chronic respiratory diseases, chronic 
cardiac diseases, immune suppression, neurological 
disorders, chronic haemoglobinopathies, diabetes 
and obesity.32 The immunoglobulin subclass, mainly 
IgG2 deficiency, has been also associated with severe 
H1N1 infection. Patients taking aspirin are at high 
risk for complications and development of fatty 
hepatitis with encephalopathy (Ray's syndrome).33
Children less than 5 years old are at higher 
risk,33 and paediatric presentations of A H1N1 2009 
can be atypical; severity is often associated with 
underlying disease, and rates of secondary bacterial 
infections are low.34 There were some case reports 
of children presenting with pneumomediastinum as 
a complication of A H1N1 2009.35 There are other 
case reports of children presenting with signs of 
influenza-like illness and seizures or altered mental 
states.36 The rate of hospital admission among 
pregnant women during the first month of the 
Influenza A H1N1 2009 outbreak was higher than 
it was in the general population (0.32 per 100,000 
pregnant women, versus 0.076 per 100,000 of the 
population at risk).37 In seasonal influenza, most 
hospitalisations occur among children less than 2 
years of age, the elderly ≥65 years of age and patients 
with certain medical conditions.29 For pandemic A 
H1N1 2009, most admissions were in young adults; 
in the USA 38% of admitted patients were young 
adults aged from 18–49 years.29 
Mortality
Annually around 3 to 5 million people suffer from 
severe seasonal influenza epidemics worldwide, 
the number of fatalities being around 250,000 to 
500,000.38 In USA, the estimated annual mortality 
caused by seasonal influenza is 23,710 or 0.91% of all 
deaths.39 The high pandemic Influenza A H1N1 2009 
mortality in Mexico was mainly due to delayed care-
seeking. The main reason for delayed care-seeking 
and mortality of Influenza A H1N1 2009 in USA 
was the lack of health insurance.40 In comparison 
with seasonal influenza, the paediatric mortality 
caused by pandemic A H1N1 2009 occurred mainly 
in children with known co-morbidities including 
chronic lung disease or immunodeficiency. The 
median age was higher than that for seasonal 
influenza (9 versus 2.7 years).41 Compared to seasonal 
influenza, the proportion of deaths in the USA was 
below the epidemic threshold.42 Some people believe 
that secondary bacterial infections were the main 
cause of high mortality in past influenza 
pandemics.43 These infections have not been 
shown to be responsible for deaths in the current 
pandemic, except in 29% of cases.44 
Investigation
People infected with Influenza A H1N1 2009 are 
assumed to be shedding the virus and potentially 
infectious one day prior to illness onset until 
resolution of fever.45 Some reports have shown 
that viral shedding may continue for at least 7 
days.46 Some patients might shed the virus for 
longer periods, for example young infants and the 
immunocompromised.45 Upper respiratory tract 
specimens are the most appropriate samples for 
laboratory testing of pandemic Influenza A H1N1 
2009. Samples should be taken from the nasopharynx 
(a nasopharyngeal swab), nasopharyngeal aspirates, 
throat swabs and transbronchial aspirates. Swab 
specimens should be collected using swabs with 
a synthetic tip (e.g. polyester or Dacron®), but not 
calcium alginate or cotton tips; the shaft should 
be made of aluminum or plastic, but not of wood. 
Specimens should be placed into sterile viral 
transport media. All respiratory specimens should 
preferably be sent immediately to the laboratory, 
but if a delay is expected they should be kept at 4°C 
for no longer than 4 days. Clinical specimens should 
be shipped on wet ice or cold packs in appropriate 
packaging.45 Influenza A H1N1 2009 virus can be 
detected in respiratory specimens by different tests. 
These tests differ in their sensitivity, specificity and 
ability to distinguish between influenza A subtypes 
(e.g. 2009 H1N1 versus seasonal H1N1 versus 
seasonal H3N2 viruses).47 
Rapid influenza diagnostic tests (RIDTs), have 
variable sensitivities and specificities, some experts 
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emergence of oseltamivir resistance; therefore, 
WHO guidelines have discouraged prescribing 
antivirals to patients with mild disease forms unless 
they have risk factors for complications.62 The 
antiviral drug of choice is oseltamivir; zanamivir 
is only indicated in patients with oseltamivir 
resistant strains. Oseltamivir is also the drug of 
choice in treatment and chemoprophylaxis for 
pregnant women; zanamivir may also be used, 
but there are less data available about its safety in 
pregnant women.57 Antibiotic chemoprophylaxis 
is not recommended in patients with H1N1 2009; 
however, when pneumonia is present, treatment 
with antibiotics should follow the recommendations 
from published evidence-based guidelines for 
community-acquired pneumonia.63
Vaccine
Universal influenza immunisation is known 
to reduce the rate of seasonal influenza and to 
decrease influenza-associated respiratory antibiotic 
prescriptions by 64%.64 WHO experts promised 
that the vaccine for influenza A H1N1 2009 would 
be available within 5–6 months from the date 
of discovery of the new pandemic virus.65 They 
estimated that first shipment would start in mid-
September and this took place. It was expected that 
vaccine manufacturing capacity would not meet 
the demand of all countries, given the fact some 
experts recommend two doses of the vaccine for 
each individual.66 The WHO estimated that 3 billion 
doses of vaccine would be produced within a one 
year period.67 Other experts claim that 4.9 billion 
could be produced within a year.68
Thirty-three influenza A H1N1 2009 vaccine 
formulations were reported, most of them based 
on whole-virion or split-virion antigens, and 12 
products would be adjuvanted (in most cases with 
aluminum hydroxide or as an oil-in water emulsion).68 
The USA Food and Drug Administration gave 
approval to four influenza A H1N1 2009 monovalent 
vaccine manufacturers in mid-September 2009. 
None of them contained adjuvants.69 The approval 
was made on the basis of standards developed 
for vaccine strain changes for seasonal influenza 
vaccines; adherence to manufacturing processes; 
product quality testing, and lot release procedures 
developed for seasonal vaccines.69 Preliminary data 
indicate that the immunogenicity and safety of these 
having reported sensitivity of 47%, and specificity of 
86%.48 Others have reported sensitivity of 51%, and 
specificity of 99%.49 Direct immunofluorescence 
(DIF) has variable sensitivities (47–93%), but high 
specificity ≥96%.49 Some reports claim that the DIF 
has a sensitivity of  93%, specificity of 97%, positive 
predictive value of 95% and negative predictive 
value of 96%.50 Viral culture was the gold standard 
for influenza virus testing; however, it is only 88.9% 
sensitive for Influenza A H1N1 2009.51 Therefore, a 
negative viral culture does not exclude infection with 
influenza A H1N1 2009.45 Some researchers have 
described detection of the virus using microarray 
techniques.52
PCR testing is highly sensitive (lower limit of 
detection, 1–10 infectious units).53 Real-time PCR 
is the test of choice for influenza A H1N1 2009.54 
It is more rapid and sensitive than cell culture.55 
However, PCR is expensive and labour intensive; 
therefore, it is impractical to investigate all affected 
patients because of the large number of people 
infected.56 It is recommended to test hospitalised 
patients with suspected influenza or patients 
for whom a diagnosis of influenza will change 
decisions regarding clinical care, infection control, 
or management of close contacts.  Patients dying 
of an acute illness, where influenza was suspected, 
should also be tested.47 
Treatment
Influenza A H1N1 2009 virus is resistant to M2 
inhibitors (amantadine and rimantadine), but 
sensitive to neuraminidase inhibitors (oseltamivir 
and zanamivir).57 Oseltamivir is an oral agent, 
while zanamivir comes in puffs for inhalation. 
Unlicensed intravenous formulation of zanamivir 
has been used successfully in treatment of ventilated 
patient not responding to oral oseltamivir.58 As of 
4th October 2009, the WHO declared the isolation 
of 31 influenza A H1N1 2009 isolates resistant 
to oseltamivir, but sensitive to zanamivir. These 
were from patients taking prolonged courses of 
oseltamivir prophylaxis.59
A meta-analysis has shown that neuraminidase 
inhibitors shorten the duration of illness in children 
with seasonal influenza and reduce household 
transmission.60 The same positive effects were 
reported in adults.61 These effects prompted 
people to use oseltamivir sooner leading to the 
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vaccines are similar to those of seasonal influenza 
vaccines.69 All influenza vaccines available in the 
United States for the 2009–10 influenza season 
are produced using embryonated hen's eggs and 
contain residual egg protein.69
There are concerns that the vaccine might cause 
Guillain-Barré syndrome (GBS) causing peripheral 
nerve damage. In 1976, the USA withdrew an 
influenza vaccine after a spike in cases of this 
neurological disease.70 Experts have disputed that 
decision, based on the argument that people would 
be more likely to get GBS as a result of the influenza 
itself rather than from the vaccine. The other 
argument against the association of the vaccine 
with GBS was that in 1976 science was less well 
developed. All influenza vaccines in the 30 years 
since 1976 have shown excellent safety records. In 
any case, a link between GBS and vaccination is 
basically impossible to demonstrate at this stage.70
A preliminary report from a randomised control 
trial in Australia for the safety and immunogenicity 
of 15 µg dose of an inactivated, split virus 2009 
H1N1 vaccine in healthy adults between the ages of 
18 and 64 years showed immunogenicity in 96.7%. 
Local discomfort (e.g. injection-site tenderness or 
pain) was reported in 46.3%. Systemic symptoms 
(e.g. headache) were reported in 45%. No deaths 
or serious adverse events were reported.71 Another 
study from UK showed that a 7.5 µg dose of 
inactivated vaccine with adjuvant was immunogenic 
to 92%, while the adjuvanted dose was only 76% 
immunogenic. The most common side effects were 
pain at the injection site in 70% and muscle aches in 
42% of subjects.72 Live seasonal influenza vaccines 
have been associated with increased respiratory 
diseases, e.g. bronchitis in children.73 
Surveil lance
Surveillance is very important at all stages of any 
pandemic. It provides information about the 
change of incidence, severity of infection, risk in 
specific groups, types of complications, appearance 
of new strains and monitors drug sensitivity. Such 
information is important for the development 
of policies regarding control measures, resource 
allocation and responses to other public health 
needs.56 The WHO suggested case-based reporting 
at the start of the pandemic, rather than shifting 
to a qualitative assessment of pandemic influenza 
activity, combined with virological sampling 
of a representative number of isolates. It also 
recommended keeping continuous records of 
influenza-like illnesses with laboratory testing for 
pandemic H1N1 in a subset of cases. The general 
population perceptions of disease magnitude, 
risk and severity are very much influenced by 
surveillance data.56 Because the world has become 
a global village, every country should implement a 
surveillance system to detect and monitor the trends 
of their viral infections to prevent the occurrence of 
future pandemics.
Conclusion
The pandemic influenza A H1N1 2009 is currently 
the most prevalent influenza virus. Most of the 
cases are mild, but there are high incidences in 
children and young adults. The presentation and 
complications are similar to those caused by 
seasonal influenza strains, but the mortality rate 
to date seems to be lower compared to seasonal 
strains. A vaccine against the pandemic strain has 
already been distributed in the markets with a very 
good safety profile. A major lesson learned from 
this pandemic is the establishment of surveillance 
systems to detect new viruses and track the trends 
of outbreaks.
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